BioVie Inc. announced the pricing of its public offering of 6,000,000 units, expected to raise approximately $12 million. Each unit consists of one share of common stock and one warrant, or a pre-funded unit. The Warrants will be listed on the Nasdaq Capital Market under the symbol “BIVIW.” The company plans to use the proceeds for working capital and general purposes. The offering is set to close on August 11, 2025, with ThinkEquity as the sole book-running manager. BioVie Inc. is a clinical-stage company developing drug therapies for liver disease and neurological disorders like Alzheimer’s and Parkinson’s disease.

Read more at GlobeNewswire: BioVie Inc. Announces Pricing of $12 Million Public